Hims & Hers Health (NYSE:HIMS) Insider Sells $694,324.50 in Stock

Key Points

• Michael Chi, an insider at Hims & Hers Health, recently sold 13,749 shares for a total of $694,324.50, reducing his stake by 4.42%.
• The stock price of Hims & Hers Health has fluctuated significantly, hitting a twelve-month high of $72.98 and low of $15.73, with the most recent price at $57.74.
• For the last quarter, the company reported earnings of $0.17 per share, slightly missing analysts' expectations, with revenue of $544.83 million, a 72.6% increase from the previous year.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Michael Chi sold 13,749 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $694,324.50. Following the completion of the sale, the insider directly owned 297,139 shares of the company's stock, valued at approximately $15,005,519.50. This trade represents a 4.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Michael Chi also recently made the following trade(s):

• On Monday, September 15th, Michael Chi sold 4,150 shares of Hims & Hers Health stock. The stock was sold at an average price of $56.00, for a total value of $232,400.00.
• On Thursday, July 24th, Michael Chi sold 2,100 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.52, for a total value of $120,792.00.
• On Wednesday, July 23rd, Michael Chi sold 13,750 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.00, for a total value of $770,000.00.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock traded down $0.05 during trading hours on Monday, reaching $57.77. 18,693,929 shares of the stock traded hands, compared to its average volume of 27,452,044. The company has a 50 day moving average price of $50.83 and a 200 day moving average price of $45.92. Hims & Hers Health, Inc. has a one year low of $16.05 and a one year high of $72.98. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The firm has a market capitalization of $13.06 billion, a price-to-earnings ratio of 72.21, a P/E/G ratio of 3.91 and a beta of 2.14.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm's quarterly revenue was up 72.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on HIMS shares. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Zacks Research cut shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Finally, Truist Financial reduced their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a report on Monday, August 18th. Two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Reduce" and a consensus target price of $38.92.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the company. Virtus Advisers LLC purchased a new position in shares of Hims & Hers Health during the second quarter valued at approximately $26,000. Quaker Wealth Management LLC purchased a new position in Hims & Hers Health during the 2nd quarter valued at $29,000. Bessemer Group Inc. boosted its holdings in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after acquiring an additional 312 shares during the period. Geneos Wealth Management Inc. bought a new position in Hims & Hers Health in the 1st quarter valued at $30,000. Finally, Skandinaviska Enskilda Banken AB publ lifted its holdings in Hims & Hers Health by 408.2% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock valued at $37,000 after buying an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.